Evidence map›Paper›PMID 29138929›Full record

ArticleWorld journal of urology2018

Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT).

Jie Sun, An Shi, Zhen Tong, Wei Xue

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Holmium laser enucleation of the prostate (HoLEP) is safe and effective in patients with high comorbidity burden.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Jie SunDepartment of Urology, Renji Hospital affiliated to Shanghai Jiao Tong University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 201200, China.
An ShiDepartment of Urology, Renji Hospital affiliated to Shanghai Jiao Tong University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 201200, China.
Zhen TongDepartment of Urology, Renji Hospital affiliated to Shanghai Jiao Tong University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 201200, China.
Wei XueDepartment of Urology, Renji Hospital affiliated to Shanghai Jiao Tong University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 201200, China. xwrenji@126.com.ORCID http://orcid.org/0000-0003-4672-5536

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT).

methodsFrom March 2013 to August 2016, we retrospectively analyzed 1124 benign prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with continuous single antiplatelet (AP) therapy (group B); 41 patients treated with single AP therapy but intermittent during preoperative time (group C) and 955 cases had no AP therapy (group D). Patients' baseline characteristics, 1-year clinical outcomes, rates of postoperative bleeding and complications were presented in this study.

resultsAll patients received successful operations and no severe postoperative complications occurred. Only one patient in Group D required transfusion. The enucleation time and catheterization time for the DAPT patients were the longest among four groups (p < 0.001, respectively). The overall complications rates within 30 days were 23.2% (13/56) in Group A, 27.8% (20/72) in Group B, 19.5% (8/41) in Group C, and 27.0% (258/955) in Group D, respectively (p = 0.678). By the 12 months, the international prostate symptom scores (IPSS), quality of life scores (QOL) and residual urine volume (RUV) in all groups have been significantly improved.

conclusionHoLEP in patients receiving DAPT after coronary artery stunting showed similar results to those achieved in patients receiving single AP therapy or non-AP therapy. It can be a good option, which the urologists can offer to those patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.

Indexed as

AgedAged, 80 and overCase-Control StudiesCoronary Artery DiseaseDrug Therapy, CombinationFeasibility StudiesHumansLasers, Solid-StateLaser TherapyMaleMiddle AgedPlatelet Aggregation InhibitorsPostoperative ComplicationsPostoperative HemorrhageProstateProstatic HyperplasiaPlatelet Aggregation InhibitorsBenign prostate hyperplasiaDual antiplatelet therapyHolmium laser enucleation of the prostateLower urinary tract symptoms

Identifiers

PMID29138929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.